Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

被引:126
作者
McCluskie, MJ
Davis, HL
机构
[1] Ottawa Hosp, Loeb Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada
[2] Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON, Canada
[3] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada
[4] Colley Pharmaceut Grp, Wellesley, MA USA
基金
英国医学研究理事会;
关键词
adjuvant; mucosal; CpG;
D O I
10.1016/S0264-410X(00)00208-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously demonstrated that synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs (CpG ODN) are potent adjuvants in mice when delivered by intramuscular, intranasal and subcutaneous routes. Herein, using tetanus toroid (TT) as a model antigen in BALB/c mice, we compared the ability of CpG ODN to induce mucosal and systemic humoral immune responses when antigen was delivered by three different routes: intrarectal, intranasal and oral. Results showed differences in immune responses with the three routes and also revealed that non-CpG "control" ODN had adjuvant effects when used at mucosal sites. This was unexpected since non-CpG ODN do not have such immunostimulatory effects in vitro or after parenteral immunization. These findings were further investigated after oral delivery of a killed influenza vaccine on its own as well as combined with TT and hepatitis B surface antigen. Our findings demonstrate that with mucosal delivery, there is a Th2 immunostimulatory effect associated with the phosphorothioate ODN backbone, and that the presence of CpG motifs shifts this towards a Th1 response. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:413 / 422
页数:10
相关论文
共 40 条
[31]   Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants [J].
Roman, M ;
MartinOrozco, E ;
Goodman, S ;
Nguyen, MD ;
Sato, Y ;
Ronaghy, A ;
Kornbluth, RS ;
Richman, DD ;
Carson, DA ;
Raz, E .
NATURE MEDICINE, 1997, 3 (08) :849-854
[32]   Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans [J].
Rudin, A ;
Johansson, EL ;
Bergquist, C ;
Holmgren, J .
INFECTION AND IMMUNITY, 1998, 66 (07) :3390-3396
[33]  
SINGH VK, 1999, IMMUNOL RES, V29, P147
[34]   STRUCTURE AND FUNCTION OF CHOLERA-TOXIN AND THE RELATED ESCHERICHIA-COLI HEAT-LABILE ENTEROTOXIN [J].
SPANGLER, BD .
MICROBIOLOGICAL REVIEWS, 1992, 56 (04) :622-647
[35]  
Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO
[36]  
2-8
[37]   Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses [J].
Staats, HF ;
Montgomery, SP ;
Palker, TJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (11) :945-952
[38]   NEW STRATEGIES FOR USING MUCOSAL VACCINATION TO ACHIEVE MORE EFFECTIVE IMMUNIZATION [J].
WALKER, RI .
VACCINE, 1994, 12 (05) :387-400
[39]   T cells on the mucosal frontline [J].
Williams, N .
SCIENCE, 1998, 280 (5361) :198-200
[40]  
Yi AK, 1996, J IMMUNOL, V157, P5394